GLP-1 Analogs When choosing a GLP-1 receptor agonist, options include long-acting vs short-acting agents, the need for reconstitution, patient preference, health insurance coverage & cost to the patient
Chaudhry, A., Gabriel, B., Noor, J., Jawad, S., & Challa, S
Armed with these, in early 1984 she set out to develop an RIA to detect their presence within the gut and pancreas
At ACR Convergence 2025, researchers from Toronto and NYU reported that PsA patients starting GLP-1 receptor agonists had significant improvements in joint counts, CRP, pain scores, and DAPSA disease activity scores within one year of treatment. Whats interesting is that you dont seem to need a large dose to see these benefits